[go: up one dir, main page]

WO2008061020A3 - Methods of treating, diagnosing or detecting cancer - Google Patents

Methods of treating, diagnosing or detecting cancer Download PDF

Info

Publication number
WO2008061020A3
WO2008061020A3 PCT/US2007/084293 US2007084293W WO2008061020A3 WO 2008061020 A3 WO2008061020 A3 WO 2008061020A3 US 2007084293 W US2007084293 W US 2007084293W WO 2008061020 A3 WO2008061020 A3 WO 2008061020A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosing
treating
detecting cancer
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/084293
Other languages
French (fr)
Other versions
WO2008061020A2 (en
WO2008061020A9 (en
Inventor
Albert Lai
Guoying K Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to AU2007319360A priority Critical patent/AU2007319360A1/en
Priority to EP07871425A priority patent/EP2084540A2/en
Priority to BRPI0718850-1A2A priority patent/BRPI0718850A2/en
Priority to JP2009536514A priority patent/JP2010509368A/en
Priority to MX2009005058A priority patent/MX2009005058A/en
Priority to CA002668714A priority patent/CA2668714A1/en
Publication of WO2008061020A2 publication Critical patent/WO2008061020A2/en
Publication of WO2008061020A3 publication Critical patent/WO2008061020A3/en
Publication of WO2008061020A9 publication Critical patent/WO2008061020A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/575—
    • G01N33/5758—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides, inter alia, methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with FZDlO overexpression.
PCT/US2007/084293 2006-11-14 2007-11-09 Methods of treating, diagnosing or detecting cancer Ceased WO2008061020A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2007319360A AU2007319360A1 (en) 2006-11-14 2007-11-09 Methods of treating, diagnosing or detecting cancer
EP07871425A EP2084540A2 (en) 2006-11-14 2007-11-09 Methods of treating, diagnosing or detecting cancer
BRPI0718850-1A2A BRPI0718850A2 (en) 2006-11-14 2007-11-09 METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER
JP2009536514A JP2010509368A (en) 2006-11-14 2007-11-09 How to treat, diagnose or detect cancer
MX2009005058A MX2009005058A (en) 2006-11-14 2007-11-09 METHODS TO TREAT, DIAGNOSE, OR DETECT CANCER.
CA002668714A CA2668714A1 (en) 2006-11-14 2007-11-09 Methods of treating, diagnosing or detecting cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85888206P 2006-11-14 2006-11-14
US60/858,882 2006-11-14

Publications (3)

Publication Number Publication Date
WO2008061020A2 WO2008061020A2 (en) 2008-05-22
WO2008061020A3 true WO2008061020A3 (en) 2008-08-07
WO2008061020A9 WO2008061020A9 (en) 2008-11-13

Family

ID=39402414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084293 Ceased WO2008061020A2 (en) 2006-11-14 2007-11-09 Methods of treating, diagnosing or detecting cancer

Country Status (9)

Country Link
EP (1) EP2084540A2 (en)
JP (1) JP2010509368A (en)
KR (1) KR20090080082A (en)
CN (1) CN101558308A (en)
AU (1) AU2007319360A1 (en)
BR (1) BRPI0718850A2 (en)
CA (1) CA2668714A1 (en)
MX (1) MX2009005058A (en)
WO (1) WO2008061020A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2479192A1 (en) 2005-10-31 2012-07-25 OncoMed Pharmaceuticals, Inc. Compositions and Methods for Diagnosing and Treating Cancer
BRPI0919473A2 (en) 2008-09-26 2017-08-29 Oncomed Pharm Inc FRIZZLED BINDING AGENTS AND THEIR USES
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
JP6355555B2 (en) 2011-04-01 2018-07-11 キアゲン Gene expression signature for WNT / B-catenin signaling pathway and use thereof
EP2742067A4 (en) * 2011-08-12 2015-03-04 Omeros Corp ANTI-FZD10 MONOCLONAL ANTIBODIES AND METHODS OF USE
WO2013157410A1 (en) * 2012-04-17 2013-10-24 Hoya株式会社 Fzd10-binding peptide
CN104768579A (en) 2012-10-23 2015-07-08 昂科梅德制药有限公司 Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
CN103048446B (en) * 2012-12-25 2015-02-04 苏州浩欧博生物医药有限公司 Luteinizing hormone nano-magnetic particle chemiluminescence assay kit and preparation method thereof and assay method thereof
CN105073195A (en) 2013-02-04 2015-11-18 昂科梅德制药有限公司 Methods of treatment with Wnt pathway inhibitors and monitoring of the treatment
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN105264381B (en) * 2013-05-16 2018-06-01 国立大学法人京都大学 Methods used to determine cancer prognosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020668A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method for treating synovial sarcoma
WO2005004912A1 (en) * 2003-07-11 2005-01-20 Oncotherapy Science, Inc. Method for treating synovial sarcoma
WO2007148417A1 (en) * 2006-06-21 2007-12-27 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to fzd10 and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020668A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method for treating synovial sarcoma
WO2005004912A1 (en) * 2003-07-11 2005-01-20 Oncotherapy Science, Inc. Method for treating synovial sarcoma
WO2007148417A1 (en) * 2006-06-21 2007-12-27 Oncotherapy Science, Inc. Tumor-targeting monoclonal antibodies to fzd10 and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUKUKAWA CHIKAKO ET AL: "Therapeutic potential of antibodies against frizzled homologue 10, a cell-surface protein, for synovial sarcoma", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATIONFOR CANCER RESEARCH, NEW YORK, NY, vol. 47, 1 April 2006 (2006-04-01), pages 465, XP002415930, ISSN: 0197-016X *
NAGAYAMA SATOSHI ET AL: "Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 24, no. 41, 15 September 2005 (2005-09-15), pages 6201 - 6212, XP002354477, ISSN: 0950-9232 *
SAITOH T ET AL: "UP-REGULATION OF FRIZZLED-10 (FZD10) BY BETA-ESTRADIOL IN MCF-7 CELLS AND BY RETINOIC ACID IN NT2 CELLS", INTERNATIONAL JOURNAL OF ONCOLOGY, ATHENS, vol. 20, no. 1, 1 January 2002 (2002-01-01), pages 117 - 120, XP008030894, ISSN: 1019-6439 *
TERASAKI H ET AL: "Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT - beta-catenin - TCF signaling pathway", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS, ATHENS, GR, vol. 9, no. 2, 1 February 2002 (2002-02-01), pages 107 - 112, XP002262585, ISSN: 1107-3756 *

Also Published As

Publication number Publication date
KR20090080082A (en) 2009-07-23
MX2009005058A (en) 2009-05-25
JP2010509368A (en) 2010-03-25
AU2007319360A1 (en) 2008-05-22
BRPI0718850A2 (en) 2014-02-25
CA2668714A1 (en) 2008-05-22
CN101558308A (en) 2009-10-14
WO2008061020A2 (en) 2008-05-22
EP2084540A2 (en) 2009-08-05
WO2008061020A9 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2007120787A3 (en) Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
WO2009036427A3 (en) Prostate cancer biomarkers
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2007134210A8 (en) Methods and compositions for the diagnosis and treatment of cancer
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2007061874A3 (en) Methods and compositions for use in treating cancer
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
WO2009092108A3 (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2008002672A3 (en) Targets for use in diagnosis, prognosis and therapy of cancer
WO2008070472A3 (en) Use of plasma hsp90 related to malignancy
WO2007056049A3 (en) Molecular profiling of cancer
WO2008092002A3 (en) Compositions and methods for treating and diagnosing pancreatic cancer
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
WO2008134020A8 (en) Ccl18 and ccl3 methods and compositions for detecting and treating cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780042179.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871425

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007871425

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007319360

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2568/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007319360

Country of ref document: AU

Date of ref document: 20071109

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2668714

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009536514

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/005058

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020097009781

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009122502

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0718850

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090513